US Patent

US8945592 — Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same

Formulation · Assigned to AcelRx Pharmaceuticals Inc · Expires 2031-07-29 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compositions and methods that minimize or eliminate oxidative degradation products in solid sufentanil dosage forms.

USPTO Abstract

Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

Patent Metadata

Patent number: US8945592
Jurisdiction: US
Classification: Formulation
Expires: 2031-07-29
Drug substance claim: No
Drug product claim: Yes
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.